Global Ferric Carboxymaltose Injection Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Ferric Carboxymaltose Injection Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Ferric carboxymaltose injection is an iron replacement product that is used to treat iron deficiency anemia (not enough iron in the blood) in patients with non-dialysis dependent chronic kidney disease (CKD), and in patients who cannot take iron supplements or who are taking iron supplements that did not work well.
Ferric Carboxymaltose Injection report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Ferric Carboxymaltose Injection market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hospital and Clinic are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Ferric Carboxymaltose Injection industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Ferric Carboxymaltose Injection key manufacturers include Daiichi Sankyo, Vifor Pharma, Hencer Pharma, Lupin, Weefsel Pharma, Apollo Pharmacy, Cipla and Bosch Pharmaceuticals, etc. Daiichi Sankyo, Vifor Pharma, Hencer Pharma are top 3 players and held % sales share in total in 2022.
Ferric Carboxymaltose Injection can be divided into 2 ml, 10 ml, 20 ml and 15 ml, etc. 2 ml is the mainstream product in the market, accounting for % sales share globally in 2022.
Ferric Carboxymaltose Injection is widely used in various fields, such as Hospital and Clinic, etc. Hospital provides greatest supports to the Ferric Carboxymaltose Injection industry development. In 2022, global % sales of Ferric Carboxymaltose Injection went into Hospital filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Ferric Carboxymaltose Injection market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Daiichi Sankyo
Vifor Pharma
Hencer Pharma
Lupin
Weefsel Pharma
Apollo Pharmacy
Cipla
Bosch Pharmaceuticals
Segment by Type
2 ml
10 ml
20 ml
15 ml
Hospital
Clinic
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Ferric Carboxymaltose Injection market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Ferric Carboxymaltose Injection, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Ferric Carboxymaltose Injection industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Ferric Carboxymaltose Injection in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Ferric Carboxymaltose Injection introduction, etc. Ferric Carboxymaltose Injection Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Ferric Carboxymaltose Injection market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Ferric Carboxymaltose Injection report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Ferric Carboxymaltose Injection market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hospital and Clinic are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Ferric Carboxymaltose Injection industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Ferric Carboxymaltose Injection key manufacturers include Daiichi Sankyo, Vifor Pharma, Hencer Pharma, Lupin, Weefsel Pharma, Apollo Pharmacy, Cipla and Bosch Pharmaceuticals, etc. Daiichi Sankyo, Vifor Pharma, Hencer Pharma are top 3 players and held % sales share in total in 2022.
Ferric Carboxymaltose Injection can be divided into 2 ml, 10 ml, 20 ml and 15 ml, etc. 2 ml is the mainstream product in the market, accounting for % sales share globally in 2022.
Ferric Carboxymaltose Injection is widely used in various fields, such as Hospital and Clinic, etc. Hospital provides greatest supports to the Ferric Carboxymaltose Injection industry development. In 2022, global % sales of Ferric Carboxymaltose Injection went into Hospital filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Ferric Carboxymaltose Injection market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Daiichi Sankyo
Vifor Pharma
Hencer Pharma
Lupin
Weefsel Pharma
Apollo Pharmacy
Cipla
Bosch Pharmaceuticals
Segment by Type
2 ml
10 ml
20 ml
15 ml
Segment by Application
Hospital
Clinic
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Ferric Carboxymaltose Injection market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Ferric Carboxymaltose Injection, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Ferric Carboxymaltose Injection industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Ferric Carboxymaltose Injection in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Ferric Carboxymaltose Injection introduction, etc. Ferric Carboxymaltose Injection Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Ferric Carboxymaltose Injection market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices